Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Feb 15;105(12):4677–4684. doi: 10.1182/blood-2004-08-3337

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2005, The American Society of Hematology

PMC Copyright notice

Figure 6. — Fas down-modulation does not modify growth or antigen specificity of EBV-CTLs. EBV-CTLs nontransduced (□) and EBV-CTLs transduced with the EV (▪), CsiRNA () or siRNA10 () after selection were cocultured with autologous LCLs with or without the addition of rIL-2 (50 U/mL). After 3 days, cells were pulsed with methyl-³H-thymidine (A). (B) A standard ⁵¹Cr release assay is shown in which CTL killing of autologous LCLs, allogeneic LCLs, and the HBS-2 cell line was tested at an effector-target ratio of 20:1. Data represent the mean ± SD of 3 and 5 different donors, respectively. (C) A representative staining is shown of EBV-CTLs using the tetramers HLA-B8-RAKFQLL and HLA-B8-QAKWRLQTL tetramers targeting BZLF1 and EBNA3A, respectively.

Inline graphic — Fas down-modulation does not modify growth or antigen specificity of EBV-CTLs. EBV-CTLs nontransduced (□) and EBV-CTLs transduced with the EV (▪), CsiRNA () or siRNA10 () after selection were cocultured with autologous LCLs with or without the addition of rIL-2 (50 U/mL). After 3 days, cells were pulsed with methyl-³H-thymidine (A). (B) A standard ⁵¹Cr release assay is shown in which CTL killing of autologous LCLs, allogeneic LCLs, and the HBS-2 cell line was tested at an effector-target ratio of 20:1. Data represent the mean ± SD of 3 and 5 different donors, respectively. (C) A representative staining is shown of EBV-CTLs using the tetramers HLA-B8-RAKFQLL and HLA-B8-QAKWRLQTL tetramers targeting BZLF1 and EBNA3A, respectively.